Takaaki Ishii, a molecular biologist, joined Taiho Ventures in 2019. He has over 11 years of oncology expertise, contributing to clinical development and licensing at Taiho Pharmaceutical.
At firms with a similar stage, sector and check size.
One email when Takaaki's firm raises a fund, adds a partner or shows new activity.

Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.
Send your deckTakaaki Ishii, a molecular biologist, joined Taiho Ventures in 2019. He has over 11 years of oncology expertise, contributing to clinical development and licensing at Taiho Pharmaceutical.
Taiho Ventures has not reported a check size. It invests at seed, series a.
A warm intro from a founder Taiho Ventures backed works best.
Taiho Pharmaceutical; Medical affairs team for Abraxane and Keytruda at Taiho Pharmaceutical; Global Portfolio Strategy Dept. at Taiho Pharmaceutical.
Last updated 2026-10-15. Is this you? Ask for a correction.